1.Perioperative Oral Functional Management of Hematopoietic Stem Cell Transplantation
Akio YASUI ; Shoichiro KITAJIMA ; Hisanobu MARUO ; Shingo TAKEI ; Naoko OWAKI ; Yuma SUZUMURA ; Harumi MIZUTANI ; Emi SAWAKI ; Mariko MIZOGUCHI ; Yuna KATO ; Hikaru OGAWA ; Akio KOHNO ; Megumi OI ; Kazumasa NAKANE ; Sayuri YAMAZAKI ; Tetsuya ANDO
Journal of the Japanese Association of Rural Medicine 2016;65(4):766-779
Hematopoietic stem cell transplantation (HSCT) involves the administration of anticancer treatment at high doses that exceed the patient’s maximum required dose for total body irradiation, to eliminate malignancy and achieve myeloablation. Hematopoietic stem cells are then transfused to re-establish the lost hematopoietic function. The use of radiation, anticancer drugs, and immunosuppressive drugs can cause adverse events in the oral cavity such as mucositis, bleeding, opportunistic infections, and graft versus host disease. This collaborative report by the departments of hematology and oncology as well as dentistry and oral surgery at our institution discusses the perioperative oral functional management of patients undergoing HSCT. Subjects enrolled were 191 transplantation patients (52 autologous, 139 allogeneic) between 2008 and 2015. The subjects underwent professional tooth cleaning before commencing a transplant conditioning regimen. When the professional oral health care (POHC) treatment was completed, professional tooth cleaning (PTC), professional mechanical tooth cleaning (PMTC), and treatment with a dental drug delivery (3DS) system were provided. This perioperative oral functional management resulted in a decrease in the frequency of oropharyngeal candidiasis from 19.3% to 4.3%. We devised a standardized supportive oral care program from the preoperative period onward to minimize adverse oral events associated with HSCT. The program could effectively improve the quality of life of patients undergoing HSCT.
2.Factors Related to Gemcitabine-induced Phlebitis
Akiko UNESOKO ; Akio KOHNO ; Nobukazu TOMITA ; Kiyoshi ISHIGURE ; Ayumi SUGIMURA ; Kazuki SATO ; Shoko ANDO
Palliative Care Research 2018;13(2):187-193
Objective: The purpose of this study was to clarify the factors related to gemcitabine (GEM)-induced phlebitis. Methods: We retrospectively analyzed 400 cases of intravenous GEM administration to 50 patients from June 2014 to May 2015. We assessed the relationship between GEM-induced phlebitis and various factors including age, sex, BMI, analgesic use (NSAIDs or opioids), and GEM-administration procedures including drug formulation, dosage, and access site. Results: Phlebitis occurred in 79 cases (19.8%). Multivariate analysis indicated that sex (female), age (<65 years old), BMI (≥25 kg/m2; obesity), drug formulation (liquid), and access site (dorsal hand vein) were significantly related to the presence of phlebitis. Discussion: GEM-administration procedures should be modified in patients with these risk factors. It is desirable to apply hot fomentation and to puncture at the brachial region or cubital fossae region vein to prevent phlebitis.